The Treatment and Management of Type 1 Diabetes Mellitus - New Insulins and Delivery Systems
Sheryl Merkin, M.S., F.N.P., C.D.E.
, Sharon Movsas, M.S., R.D., C.D.E.
and Joel Zonszein, M.D., C.D.E.
Dr. Zonszein is Professor of Clinical Medicine, Albert Einstein College of Medicine. All authors are staff members of the Clinical Diabetes Center of Montefiore Medical Center, New York.
Within the past 12 months, Dr. Zonszein has been on the Speakers Bureau of Merck, Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly & Co. and Novo Nordisk; Ms. Merkin has been on the Speakers Bureau of Sanofi Aventis and Novo Nordisk ; Ms. Movsas reports no commercial conflicts of interest.
Estimated time to complete:
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- State the recommendations for glucose monitoring and diet in individuals receiving intensive insulin therapy
- Explain the basic principles of insulin replacement hormone utilizing basal/bolus regimens
- Identify the new insulins and new insulin delivery systems.